Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neuronetics, Inc. - Common Stock (NQ:STIM)

3.880 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neuronetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Neuronetics Inks Six-Year Exclusive Partnership With Greenbrook TMS
Via Benzinga
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety 
From Neuronetics
Via GlobeNewswire
Neuronetics Settles Unfair Competition Related Litigation Against BrainsWay
Via Benzinga
Neuronetics's Return On Capital Employed Overview
Via Benzinga
Short Volatility Alert: Neuronetics, Inc.
On Thursday, shares of Neuronetics, Inc. (NASDAQ: STIM) experienced volatile short activity. After the activity, the stock price went down -1.74% to $2.83. The overall sentiment for STIM has been... 
Via Benzinga
Short Volatility Alert: Neuronetics, Inc.
On Thursday, shares of Neuronetics, Inc. (NASDAQ: STIM) experienced volatile short activity. After the activity, the stock price went up +0.76% to $2.65. The overall sentiment for STIM has been... 
Via Benzinga
Despite Competition This Analyst Finds BrainsWay Attractive
Via Benzinga
Recap: Neuronetics Q2 Earnings
  Neuronetics (NASDAQ:STIM) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
NeuroStar’s technology once again recognized as an effective non-drug treatment for patients 
From Neuronetics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapy 
From Neuronetics
Via GlobeNewswire
Read Why Neuronetics Shares Are Trading Higher Today
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
Neuronetics Announced as Winner by 2022 Merit Awards for Technology
NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental health 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health
Published and Proposed Medicare Coverage through CGS and NGS MACs Will Reduce Number of Medication Trials, Leading to Increased Eligibility for TMS 
From Neuronetics
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million. 
Via Benzinga
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
  
Via Benzinga
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion. 
Via Benzinga
Neuronetics's Earnings: A Preview
Neuronetics (NASDAQ:STIM) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Neuronetics will... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Investors ready to start trading early this morning will want to check out the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness... 
Via Benzinga
NCR Stock Pops 13% on Buyout News
NCR (NCR) stock is rising higher on Tuesday following reports that private-equity firm Veritas wants to buy the company and take it private. 
Via InvestorPlace
Why Is Neuronetics (STIM) Stock Up 12% Today?
Neuronetics (STIM) stock is taking off on Tuesday after the announcing approval from the FDA for a new use of a metal health treatment. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback